Elisabetta Filomena Buonaguro

Elisabetta Filomena Buonaguro

Auto-generated profile, based on publicly available information

Elisabetta Filomena Buonaguro

Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences, University of Naples “Federico II”, 80131 Napoli, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Carmine TomasettiCarmine Tomasetti
Carmine Tomasetti
Felice IasevoliFelice Iasevoli
Felice Iasevoli
EBElisabetta Filomena Buonaguro
Elisabetta Filomena Buonaguro
Domenico De BerardisDomenico De Berardis
Domenico De Berardis
Michele FornaroMichele Fornaro
Michele Fornaro
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis
Dopamine-glutamate interplay dysfunctions have been suggested as pathophysiological key determinants of major psychotic disorders, above all schizophrenia and mood disorders. For the most part, synaptic interactions between dopamine and glutamate signaling pathways take part in the postsynaptic density, a specialized ultrastructure localized under the membrane of glutamatergic excitatory synapses. Multiple proteins, with the role of adaptors, regulators, effectors, and scaffolds compose the postsynaptic density network. They form structural and functional crossroads where multiple signals, starting at membrane receptors, are received, elaborated, integrated, and routed to appropriate nuclear targets. Moreover, transductional pathways belonging to different receptors may be functionally interconnected through postsynaptic density molecules. Several studies have demonstrated that psychopharmacologic drugs may differentially affect the expression and function of postsynaptic genes and proteins, depending upon the peculiar receptor profile of each compound. Thus, through postsynaptic network modulation, these drugs may induce dopamine-glutamate synaptic remodeling, which is at the basis of their long-term physiologic effects. In this review, we will discuss the role of postsynaptic proteins in dopamine-glutamate signals integration, as well as the peculiar impact of different psychotropic drugs used in clinical practice on postsynaptic remodeling, thereby trying to point out the possible future molecular targets of “synapse-based” psychiatric therapeutic strategies.


1 April 2014 in Schizophrenia Research
Verified
Journal Article
Closed access
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis
Carmine TomasettiCarmine Tomasetti
Carmine Tomasetti
EBElisabetta F. Buonaguro
Elisabetta F. Buonaguro
GLGianmarco Latte
Gianmarco Latte
RRRodolfo Rossi
Rodolfo Rossi
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis

31 December 2013 in Current Signal Transduction Therapy
Verified
Journal Article
Closed access
PDF file
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis
LALivia Avvisati
Livia Avvisati
GLGianmarco Latte
Gianmarco Latte
EBElisabetta F. Buonaguro
Elisabetta F. Buonaguro
Carmine TomasettiCarmine Tomasetti
Carmine Tomasetti
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis
Abstract: The NMDA receptor non-competitive antagonist ketamine is regarded to model multiple symptomatic domains and molecular dysfunctions of schizophrenia, depending on acute or chronic exposure to the drug. In this work, we aimed to investigate whether ketamine may induce changes in the expression of transcripts relevant for the dopaminergic system (i.e. dopamine D1, D1R, and D2 receptors, D2R, dopamine transporter, DAT) and whether these changes were differentially modulated by acute vs. subchronic exposure. Acute ketamine decreased D1R expression in the ventrolateral caudate-putamen. Subchronic ketamine did not affect D1R and D2R expression. Increased D2R and DAT expression by subchronic ketamine was found in the midbrain. Distribution of mRNA expression showed sharp differences after acute vs. subchronic treatments for all transcripts. Subchronic ketamine induced an upergulation of D2R and DAT mRNA transcripts in the midbrain, since expression was significantly increased compared to both subchronic and acute vehicle-mediated expression. The observed molecular changes by acute vs. subchronic ketamine may model different steps in psychosis pathophysiology involving dopaminergic system.

1 April 2014 in Schizophrenia Research
Verified
Journal Article
Closed access
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis
SGSara Giordano
Sara Giordano
RBRaffaele Balletta
Raffaele Balletta
LALivia Avvisati
Livia Avvisati
GLGianmarco Latte
Gianmarco Latte
Andrea De BartolomeisAndrea De Bartolomeis
Andrea De Bartolomeis